<i>POLRMT</i> as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients

<i>POLRMT</i> as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients

Anthracyclines are among the most used chemotherapeutic agents in breast cancer (BC). However their use is hampered by anthracycline-induced cardiotoxicity (AIC). The currently known clinical and genetic risk factors do not fully explain the observed inter-individual variability and only have a limi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alejandro Velasco-Ruiz, Rocio Nuñez-Torres, Guillermo Pita, Hans Wildiers, Diether Lambrechts, Sigrid Hatse, Danielle Delombaerde, Thomas Van Brussel, M. Rosario Alonso, Nuria Alvarez, Belen Herraez, Christof Vulsteke, Pilar Zamora, Teresa Lopez-Fernandez, Anna Gonzalez-Neira
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
anthracyclines
cardiotoxicity
epirubicin
breast cancer
adverse drug reaction
<i>POLRMT</i>
Pharmacy and materia medica
RS1-441
Acceso en línea:https://doaj.org/article/fc41170d71e949d6a10cde030ad32cba
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/fc41170d71e949d6a10cde030ad32cba

Ejemplares similares